CoChat

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Open access

Published version of a preprint

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually have functional repair defects remains unknown. Here, we devise a platform for functional profiling of DNA repair in short-term patient-derived HGSC organoids. We tested 33 organoid cultures derived from 22 patients with HGSC for defects in homologous recombination (HR) and replication fork protection. Regardless of DNA repair gene mutational status, a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity. A functional defect in replication fork protection correlated with carboplatin and CHK1 and ATR inhibitor sensitivity. Our results indicate that a combination of genomic analysis and functional testing of organoids allows for the identification of targetable DNA damage repair defects. Larger numbers of patient-derived organoids must be analyzed to determine whether these assays can reproducibly predict patient response in the clinic. Significance: Patient-derived ovarian tumor organoids grow rapidly and match the tumors from which they are derived, both genetically and functionally. These organoids can be used for DNA repair profiling and therapeutic sensitivity testing and provide a rapid means of assessing targetable defects in the parent tumor, offering more suitable treatment options. Cancer Discov; 8(11); 1404–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-0474

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 50 references

Cited by

See all 457

Metadata

Authors
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., Yang, C., Morizane, R., Kochupurakkal, B. S., Do, K. T., Konstantinopoulos, P. A., Liu, J. F., Bonventre, J. V., Matulonis, U. A., Shapiro, G. I., Berkowitz, R. S., Crum, C. P., & D'Andrea, A. D.
Affiliations
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
  • University of Washington (US)
  • Dana-Farber Cancer Institute (US)
  • 1Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Venue
Cancer Discovery
Published
2018-11-01
Volume
8
Issue
11
Pages
1404-1421
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2891058330
Cited by
452
References
49
Citations by year
2026: 37 · 2025: 43 · 2024: 67 · 2023: 78 · 2022: 66 · 2021: 72 · 2020: 63 · 2019: 25 · 2018: 1
FWCI
15.13
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Stand Up to Cancer (SU2C) (SU2C-AACR-DT16-15)
  • HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (R37HL052725, P01HL048546)
  • U.S. Department of Defense (DOD) (BC151331P1)
  • Leukemia and Lymphoma Society (LLS) (6237-13)
  • Breast Cancer Research Foundation (BCRF)
  • Richard and Susan Smith Family Foundation
  • The Bridge Project
  • HHS | NIH | National Cancer Institute (NCI) (UM1 CA186709)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
high-grade serous ovarian cancer, DNA repair deficiency, patient-derived tumor organoids, homologous recombination deficiency, replication fork protection, PARP inhibitor sensitivity, carboplatin sensitivity, CHK1 inhibitor, ATR inhibitors, predictive biomarkers, targeted therapy
MeSH terms
Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, DNA Repair, DNA Replication, Female, Follow-Up Studies, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Organ Culture Techniques, Organoids, Ovarian Neoplasms, Prognosis, Pyrazines, Pyrazoles, Biomarkers, Tumor, Carboplatin, Cystadenocarcinoma, Serous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. https://app.cochat.ai/papers/10.1158/2159-8290.cd-18-0474
The paper
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., Yang, C., Morizane, R., Kochupurakkal, B. S., Do, K. T., Konstantinopoulos, P. A., Liu, J. F., Bonventre, J. V., Matulonis, U. A., Shapiro, G. I., . . . D'Andrea, A. D. (2018). Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-18-0474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.